Cellebrite (NASDAQ: CLBT), a global leader in premier Digital
Investigative solutions for the public and private sectors, today
announced a series of Board updates to support the Company’s
continued growth into 2025 and beyond.
As previously detailed on November 6, 2024, Thomas E. Hogan has
been appointed interim CEO to begin 2025 as part of a planned
leadership transition. In conjunction with stepping into this
position, Mr. Hogan remains on the Company’s Board of Directors and
plans to revert to his position as chairman upon the eventual
appointment of a new CEO.
As part of Cellebrite’s ongoing commitment to best practices in
board governance, specifically those related to the separation of
duties between the CEO and board chair, Adam H. Clammer, Managing
Partner of True Wind Capital Management and Cellebrite’s current
lead independent director, has assumed the duties of board
chairman.
Finally, Cellebrite is pleased to announce that Michael D.
Capellas, a distinguished executive with extensive leadership
experience across a range of CIO, CEO and board chairman and
director positions at a number of the world’s most successful
software and technology companies, has been appointed to
Cellebrite’s Board of Directors as a Class II director. In
addition, he will serve as the Board’s lead independent director,
replacing the role vacated by Adam Clammer. All appointments were
effective January 1, 2025.
Michael D. Capellas has served as founder and CEO of Capellas
Strategic Partners, a strategic technology advisory firm, since
November 2012. His leadership experience includes serving as the
founding Chairman and CEO of VCE (Virtual Computing Company) a
joint venture between Cisco, EMC and VMware, which developed and
commercialized an innovative platform for cloud computing; Chairman
and CEO of First Data Corporation; CEO and director of MCI
(previously WorldCom); Chairman, President and CEO of Compaq
Computer Corporation and President of Hewlett-Packard Company
following the merger of Compaq and Hewlett-Packard. Mr. Capellas
currently serves as the lead independent director of Cisco Systems,
Inc. (NASDAQ: CSCO) in addition to other current and past board
assignments.
“I am personally delighted to welcome Michael to our board,”
said Thomas E. Hogan. “Michael brings a wide range of powerful and
complementary skills to an already strong board. His specific depth
of experience as the CEO of multiple global leaders with the scale
we aspire to, his prowess in products and technology as a legacy
CIO and his track record of strategic insight and execution, align
perfectly with Cellebrite’s priorities and ambitions.”
“I am thrilled to join Cellebrite’s board,” said Mr. Capellas.
“I have a deep passion for justice, safety and security, and I
bring a long history of global support for these causes.
Cellebrite’s C2C platform empowers law enforcement, intelligence
agencies and global leaders to accelerate justice and enhance
community safety. I am particularly inspired by the Company’s
ongoing efforts to combat child exploitation and trafficking – an
issue I care about deeply. I look forward to collaborating with
Tom, Adam, my fellow board directors and Cellebrite’s executive
team to further the Company’s mission and drive meaningful
impact.”
Cellebrite’s Board of Directors continues to be composed of 10
members. Detailed biographies of all Cellebrite directors are
available here.
References to Websites and Social Media
PlatformsReferences to information included on, or
accessible through, websites and social media platforms do not
constitute incorporation by reference of the information contained
at or available through such websites or social media platforms,
and you should not consider such information to be part of this
press release.
Caution Regarding Forward Looking
StatementsThis document includes “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the United States Private Securities Litigation Reform Act of 1995.
Forward looking statements may be identified by the use of words
such as “forecast,” “intend,” “seek,” “target,” “anticipate,”
“will,” “appear,” “approximate,” “foresee,” “might,” “possible,”
“potential,” “believe,” “could,” “predict,” “should,” “could,”
“continue,” “expect,” “estimate,” “may,” “plan,” “outlook,”
“future” and “project” and other similar expressions that predict,
project or indicate future events or trends or that are not
statements of historical matters. Such forward-looking statements
include Mr. Hogan’s plans to revert to his position as chairman
upon the eventual appointment of the new CEO; and Mr. Capellas’
intention to collaborate with Cellebrite’s board members and
executive team to further the Company’s mission and drive
meaningful impact. Such forward-looking statements including those
with respect to commentary associated with future performance,
strategies, prospects, and other aspects of Cellebrite’s business
are based on current expectations that are subject to risks and
uncertainties. A number of factors could cause actual results or
outcomes to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to: Cellebrite’s ability to keep pace with technological
advances and evolving industry standards; Cellebrite’s material
dependence on the purchase, acceptance and use of its solutions by
law enforcement and government agencies; real or perceived errors,
failures, defects or bugs in Cellebrite’s DI solutions;
Cellebrite’s failure to maintain the productivity of sales and
marketing personnel, including relating to hiring, integrating and
retaining personnel; intense competition in all of Cellebrite’s
markets; the inadvertent or deliberate misuse of Cellebrite’s
solutions; failure to manage its growth effectively; Cellebrite’s
ability to introduce new solutions and add-ons; its dependency on
its customers renewing their subscriptions; the low volume of
business Cellebrite conducts via e-commerce; risks associated with
the use of artificial intelligence; the risk of requiring
additional capital to support the growth of its business; risks
associated with higher costs or unavailability of materials used to
create its hardware product components; fluctuations in foreign
currency exchange rates; lengthy sales cycle for some of
Cellebrite’s solutions; near term declines in new or renewed
agreements; risks associated with inability to retain qualified
personnel and senior management; the security of Cellebrite’s
operations and the integrity of its software solutions; risks
associated with the negative publicity related to Cellebrite’s
business and use of its products; risks related to Cellebrite’s
intellectual property; the regulatory constraints to which
Cellebrite is subject; risks associated with Cellebrite’s
operations in Israel, including the ongoing Israel-Hamas war and
the risk of a greater regional conflict; risks associated with
different corporate governance requirements applicable to Israeli
companies and risks associated with being a foreign private issuer
and an emerging growth company; market volatility in the price of
Cellebrite’s shares; changing tax laws and regulations; risks
associated with joint, ventures, partnerships and strategic
initiatives; risks associated with Cellebrite’s significant
international operations; risks associated with Cellebrite’s
failure to comply with anti-corruption, trade compliance,
anti-money-laundering and economic sanctions laws and regulations;
risks relating to the adequacy of Cellebrite’s existing systems,
processes, policies, procedures, internal controls and personnel
for Cellebrite’s current and future operations and reporting needs;
and other factors, risks and uncertainties set forth in the section
titled “Risk Factors” in Cellebrite’s annual report on Form 20-F
filed with the SEC on March 21, 2024 and as amended on April 12,
2024, and in other documents filed by Cellebrite with the U.S.
Securities and Exchange Commission (“SEC”), which are available
free of charge at www.sec.gov. You are cautioned not to place undue
reliance upon any forward-looking statements, which speak only as
of the date made, in this communication or elsewhere. Cellebrite
undertakes no obligation to update its forward-looking statements,
whether as a result of new information, future developments or
otherwise, should circumstances change, except as otherwise
required by securities and other applicable laws.
About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers
to protect and save lives, accelerate justice and preserve privacy
in communities around the world. We are a global leader in Digital
Investigative solutions for the public and private sectors,
empowering organizations in mastering the complexities of legally
sanctioned digital investigations by streamlining intelligence
processes. Trusted by thousands of leading agencies and companies
worldwide, Cellebrite’s Digital Investigation platform and
solutions transform how customers collect, review, analyze and
manage data in legally sanctioned investigations. To learn more,
visit us at www.cellebrite.com, https://investors.cellebrite.com,
or follow us on Twitter at @Cellebrite.
Contacts:
Investors Relations
Andrew KramerVice President, Investor
Relationsinvestors@cellebrite.com+1 973.206.7760
Media
Victor Ryan CooperSr. Director of Corporate Communications +
Content OperationsVictor.cooper@cellebrite.com+1 404.804.5910
Cisco Systems (NASDAQ:CSCO)
Historical Stock Chart
From Dec 2024 to Jan 2025
Cisco Systems (NASDAQ:CSCO)
Historical Stock Chart
From Jan 2024 to Jan 2025